Abstract
AbstractModern vaccine design has sought a minimalization approach, moving to the isolation of antigens from pathogens that invoke a strong neutralizing immune response. This approach has created safer vaccines but may limit vaccine efficacy due to poor immunogenicity. To combat global diseases such as COVID-19, malaria, and AIDS there is a clear urgency for more effective next-generation vaccines. One approach to improve the immunogenicity of vaccines is the use of nanoparticle platforms that present a repetitive array of antigen on its surface. This technology has been shown to improve antigen presenting cell uptake, lymph node trafficking, and B-cell activation through increased avidity and particle size. With a focus on design, we summarize natural platforms, methods of antigen attachment, and advancements in generating self-assembly that have led to new engineered platforms. We further examine critical parameters that will direct the usage and development of more effective platforms.
Funder
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference99 articles.
1. FDA. Drug Products, Including Biological Products, that Contain Nanomaterials—Guidance for Industry, https://www.fda.gov/media/109910/download (FDA, 2017).
2. Zhao, L. et al. Nanoparticle vaccines. Vaccine 32, 327–337 (2014).
3. Song, C. et al. Recent advances in particulate adjuvants for cancer vaccination. Adv. Therapeutics 3, 1900115 (2020).
4. Shin, H. et al. Recent advances in RNA therapeutics and RNA delivery systems based on nanoparticles. Adv. Therapeutics 1, 1800065 (2018).
5. López-Sagaseta, J., Malito, E., Rappuoli, R. & Bottomley, M. J. Self-assembling protein nanoparticles in the design of vaccines. Comput. Struct. Biotechnol. J. 14, 58–68 (2016).
Cited by
127 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献